FURTHER EXPLORATION OF ADRENOMEDULLIN AS A NOVEL THERAPEUTIC PEPTIDE FOR LUPUS NEPHRITIS USING MRL/FAS LPR MOUSE MODEL by KOW NIEN YEE
I 
 
FURTHER EXPLORATION OF 
ADRENOMEDULLIN AS A NOVEL 
THERAPEUTIC PEPTIDE FOR LUPUS NEPHRITIS 
USING MRL/Fas
lpr





KOW NIEN YEE 




A THESIS SUBMITTED 
FOR THE DEGREE OF MASTER OF SCIENCE 
DEPARTMENT OF MEDICINE 







I hereby declare that the thesis is my original work and it has been written by 
me in its entirety. I have dully acknowledged all the sources of information 
which have been used in the thesis.  
 







KOW NIEN YEE 








I would like to express my deepest gratitude to my supervisor, Dr. 
Anselm Mak, for his continuous guidance, thoughtful supervision, strong 
support and great encouragement. Throughout my entire Master program, I 
have learned not only the scientific knowledge and laboratory skills, but also 
the dedication and commitment to research that he has demonstrated. 
I wish to express my sincere appreciation to A/P. Koh Dow Rhoon for 
his kindness in providing the laboratory space and equipment. I would also 
like to thank Madam Ho Chiu Han, research assistant, for her assistance in 
coordinating the laboratory issues. 
I would like to thank my colleagues both in NUS and the Singapore 
Immunology Network (SIgN) for their kind help. My gratitude goes to Dr. 
Anna-Marie Fairhurst for her guidance and advice throughout the project. In 
addition, I would also like to thank Miss Alicia Cheak Ai Cia and Miss Lee 
Hui Yin for their technical advice and skills in flow cytometry; to Mr. Ren 
Tao for his technical assistance and to Miss Wong Junyi Nicole, Miss 











TABLE OF CONTENTS 
DECLARATION ............................................................................................... I 
ACKNOWLEDGMENT................................................................................... II 
TABLE OF CONTENTS ................................................................................. III 
SUMMARY ...................................................................................................... V 
LIST OF TABLES ......................................................................................... VII 
LIST OF FIGURES ...................................................................................... VIII 
LIST OF ABBREVIATIONS ........................................................................... X 
CHAPTER 1 INTRODUCTION ....................................................................... 1 
1.1 Overview of systemic lupus erythematosus ............................................. 1 
1.2. Immunopathology of SLE ....................................................................... 3 
1.2.1 Loss of tolerance to self-antigens in the lymphocytes ....................... 3 
1.2.2 Impaired Apoptosis in SLE ............................................................... 6 
1.3 A Review of adrenomedullin ................................................................... 9 
1.4 ADM and the immune system ................................................................ 15 
1.5 ADM and glomerulonephritis ................................................................ 18 
1.6 MRL/Fas
lpr 
murine model ....................................................................... 22 
1.6.1 Phenotypes of MRL/ Fas
lpr
 mice ..................................................... 22 
1.6.2 Genetics of MRL/ Fas
lpr
 mice .......................................................... 23 
1.6.3 Immunopathogenesis of MRL/Fas
lpr
 mice ....................................... 24 
1.7 Aims and Objectives .............................................................................. 27 
CHAPTER 2 MATERIALS AND METHOD ................................................. 28 
2.1 Reagents ................................................................................................. 28 
2.2 Instruments and Software ....................................................................... 29 
2.3 Methods of Study ................................................................................... 30 
2.3.1 Mouse model ................................................................................... 30 
2.3.2 Treatment groups ............................................................................. 30 
2.3.3 Blood collection and serological analysis ....................................... 31 
2.3.4 Measurement of the levels of protein and red blood cells in the urine
 .................................................................................................................. 32 
IV 
 
2.3.5 Preparation of single-cell suspensions of splenocytes, flow 
cytometry and fluorescent activated cell sorting (FACS) ........................ 32 
2.3.6 Histological studies of kidneys ........................................................ 33 
2.3.7 In vitro study of the impact of ADM on splenocytes ...................... 34 
2.3.8 Statistical analyses ........................................................................... 35 
CHAPTER 3 RESULTS .................................................................................. 36 
3.1 ADM treatment reduced splenomegaly and lymphadenopathy ............. 36 
3.2 Serum levels of anti-dsDNA, anti-Sm, anti-ribosomal P, anti-SSA 52 
and anti-SSA 60 antibodies were not affected by ADM treatment .............. 39 



















 macrophages .... 43 
3.4 Effect of ADM on proteinuria and hematuria ........................................ 46 
3.5 Renal deposition of C1q, C3, anti-dsDNA antibody, IgA, IgG, and IgM 
immunoglobulins were affected by ADM treatment in the late intervention 
group............................................................................................................. 49 









B cell proliferation in cultured splenocytes from MRL/Fas
lpr 
mice at low 
dose of CpGb ................................................................................................ 64 
CHAPTER 4 DISCUSSION ............................................................................ 68 
CHAPTER 5 CONCLUSION.......................................................................... 75 
CHAPTER 6 FUTURE WORK ...................................................................... 76 












Systemic lupus erythematosus (SLE) is a chronic, inflammatory 
autoimmune disease characterized by the production of a wide range of 
autoantibodies. The disease activity of SLE has been found to be correlated 
with the level of plasma adrenomedullin (ADM) in patients with SLE. ADM is 
a novel peptide that consists of 52 amino acids and was first identified in 
human phaeochromoctyoma. It has been demonstrated that ADM behaves as a 
potent vasodilator and also plays an important role in mediating the immune 
system. The objective of this study was to investigate the effect of ADM on 
the disease progression of lupus-like disease and glomerular deposition of 
immune complexes in MRL/Fas
lpr
 (MRL/lpr) autoimmune mice. Besides, the 
effect of ADM on cultured splenocytes extracted from MRL/lpr mice was also 
investigated.  
To carry out the investigations, MRL/lpr mice were assigned into 
early- and late intervention groups (n=8 and n=7 respectively). The early 
intervention group received intraperitoneal (IP) injection of ADM and saline 
as control thrice weekly, starting at the age of 6 weeks for a total period of 18 
weeks. The late intervention group received IP injection of ADM, 
prednisolone and saline thrice weekly, starting at the age of 12 weeks for a 
total period of 6 weeks. For the in vitro assay, splenocytes from untreated 
MRL/lpr mice were stimulated with a B cell stimulant (CpGb 
oligodeoxynucleotides) and a T cell stimulant (anti-CD3/CD28 antibodies) 
and these cells were co-cultured with and without ADM.  
By comparing the average weight of the spleens and lymph nodes, it 
was found that ADM significantly reduced lymphadenopathy but not 
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splenomegaly in both the early- and late intervention groups. Serological 
analysis revealed that ADM did not affect the levels of autoantibodies 
including anti-dsDNA, anti-Smith, anti-ribosomal P, anti-SSA 52, and anti-
SSA 60 in both the early- and late intervention groups. Proteinuria and 
hematuria tended to be reduced by ADM treatment in both the early- and late 









splenocytes were not significantly reduced by ADM when compared with their 
respective control groups, in both the early- and late intervention groups. 
While there was no reduction of glomerular autoantibody deposition by ADM 
observed in the early intervention group, ADM significantly reduced the 
glomerular autoantibody deposition of C1q, C3, anti-dsDNA, IgA, IgG, and 
IgM in the late intervention group as shown by immunofluorescent staining. 
For the in vitro study, ADM treatment decreased the proliferation and 
increased the apoptosis of B220
+
 cells at low concentration of CpGb while 
those of CD4
+ 
cells were not affected by ADM. 
In conclusion, the above findings suggested that ADM might play a 
role in regulating proliferation and apoptosis of the B lymphocytes, and the 
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CHAPTER 1 INTRODUCTION 
1.1 Overview of systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a chronic, inflammatory 
autoimmune disease which predominantly affects females during their child-
bearing years (Bauer et al. 2006; Crispín et al. 2010). The prevalence of SLE 
is around 1:1,000 in most reported series, and it is more common and severe in 
African American, Asian, and Hispanic patients than in their Caucasians 
counterparts (Crispín et al. 2010; Gladman et al. 1999). Clinical presentation 
of SLE may range from mild diseases such as malar rash or arthralgia to 
severe major organ manifestations like neuropsychiatric lupus or severe lupus 
nephritis (Crispín et al. 2010). Pathogenetically, SLE is believed to be initiated 
by the loss of tolerance to self-antigens and subsequent production of a broad 
range of autoantibody including the anti-double stranded (ds) DNA antibody 
which leads to immune-mediated inflammation affecting many organs 
(Crispín et al. 2010; Choi et al. 2012). While the exact aetio-pathogenesis of 
SLE remains largely elusive, the interplay between environmental, 
neuroendocrine, hormonal and genetic factors appears to be involved (Mok 
and Lau, 2003).   
With better understanding of the pathogenic mechanism of SLE, and 
the growing treatment armamentarium of the condition and its complications, 
the prognosis of SLE has improved tremendously over the past few decades 
(Mak et al. 2012). The 5-year survival rate of patients with SLE in most 
reported series during the 1990s is higher than 90%, as compared with only 
around 50-60% during the 1950s and 1960s (Cervera et al. 1999; Mok et al, 
2000; Mok 2005).  Nevertheless, the overall survival of patients with SLE has 
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not improved much since the 1980s (Mak et al. 2012). A recent global meta-
analysis of over 70 studies demonstrated that damage in the renal and 
neuropsychiatric system has been slowing down the improvement of the 
overall survival in patients with SLE (Mak et al. 2012).  
Currently, clinicians mainly base on patients’ history, physical 
examination and routine laboratory parameters such as serum anti-dsDNA and 
complement levels, and proteinuria (in case of active lupus nephritis) to 
determine the activity of SLE (Gladman et al. 1999). As far as treatment of 
lupus is concerned, depending of the severity of the disease, most patients are 
given immunosuppressive therapies which include glucocorticoids and an 
immunosuppressant. However, the unfavourable side-effects profile of 
glucocorticoids and most of the current immunosuppressants render physicians 
and scientists yearning for better therapeutic agents for lupus which are less 
immunosuppressive and safer with fewer side effects such as infection, 









1.2. Immunopathology of SLE 
1.2.1 Loss of tolerance to self-antigens in the lymphocytes 
Adaptive immunity is an antigen-specific defence mechanism that is 
regulated by the B and T lymphocytes (Thornton and Morgan 2009). During 
the development of the lymphocytes, self and non-self antigens are presented 
to these lymphocytes via the interactions of specific receptors (Liu and 
Davidson 2012). In normal circumstance, autoreactive T and B cells are 
centrally eliminated by clonal deletion, receptors reprogramming or are 
suppressed by regulatory cells in the thymus and bone marrow which render 
the potentially autoreactive cells immunologically unresponsive or anergic 
(Liu and Davidson 2012). In the periphery, activated and matured 
lymphocytes that possess high affinity to self-antigen are eliminated or 
suppressed in a similar manner which happens in the thymus and bone marrow 
(Liu and Davidson 2012). These regulatory mechanisms are important in 
maintaining the central and peripheral immune tolerance (Thornton and 
Morgan 2009). In SLE, immune tolerance is disrupted either by genetic or 
environmental factors or both of them (Liu and Davidson 2012). Genetic 
polymorphisms of the major histocompatibility complex (MHC) and those of 
the non-MHC related genes such as those encode the complement proteins, T 
cell receptor (TCR), and mannose binding lectin are advocated to take part in 
the loss of immune tolerance in SLE (Mok and Lau 2003). In addition, 
environmental factors including epigenetic changes and exposures to bacterial 
DNA, cell wall phospholipids and viral antigens also contribute to the 
breakdown of immune tolerance in patients with lupus (Mok and Lau 2003).  
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The hallmark of SLE is the production of a broad range of 
autoantibodies (Mok and Lau 2003). Due to this reason, defects in B cells 
tolerance have been postulated to be the central player in the pathogenesis of 
SLE (Nashi et al. 2010). A few studies showed that in SLE, some of the 
tolerance checkpoints of the B cells were defective (Liu and Davidson 2011). 
By tracking the VH4-34 heavy chain gene which is a gene encode autoreactive 
antibodies in B cells, Pugh-Bernard et al identified a defective checkpoint at 
the germinal centre (GC) entry point in patients with SLE (Pugh-Bernard et al. 
2001). This defect allows the lupus B cells to further differentiate into plasma 
cells and produce autoantibodies (Pugh-Bernard et al. 2001). In another study 
that utilised a synthetic peptide that specifically tracks B cells that targets 
DNA, the tolerance checkpoint between naïve and antigen-experienced B cells 
was shown to be impaired in patients with SLE (Jacobi et al. 2009). Besides, 
enhanced activation of survival and stimulatory receptors such as B cell 
receptor (BCR), toll-like receptor (TLR), and B cell activating factor (BAFF) 
or reduced signalling of the inhibitory Fc receptor (FcγRIIB) can also lead to 
autoreactivity in SLE (Liu and Davidson 2012; Liu and Davidson 2011).  
Furthermore, increased expression of interleukin (IL)-6 and CD19 that 
stimulate BCR can promote survival and activation of B cells (Liu and 
Davidson 2012).   A number of studies have demonstrated that serum IL-6 was 
elevated in patients with SLE and the lupus B cells were found to be more 
sensitive to the stimulatory effects of IL-6 than non-SLE B cells (Ripley et al. 
2005; Lacki et al. 1997; Linker-Israeli et al. 1991). A recent study 
demonstrated that in patients with SLE, the expression of FcγRIIB on 
peripheral memory B cells was lower than that of healthy controls (Mackay 
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2006). Since FcγRIIB provides inhibitory signals that suppress the activation 
of B cells through the BCR, its reduction will increase the survival of 
autoreactive B cells (Mackay 2006). Besides taking part in producing 
autoantibodies, B cells can also act as antigen presenting cells (APCs) 
(Mamula et al. 1994; Constant et al. 1995). B cells present autoantigens which 
activate T cells through the interaction of the MHC peptides and TCR, 
accompanied by other co-stimulatory molecules such as CD86 and CD40 
(Nashi et al. 2010). Subsequently, activated autoreactive T cells aggravate the 
autoimmune response by further stimulating the production of autoantibodies 
and pro-inflammatory cytokines such as IL-17 and interferon-gamma (IFN-γ) 
(Crispín et al. 2010).  
In addition to B cells, growing evidence has shown that T cells 
abnormalities contribute to the pathogenesis of SLE (Crispín et al. 2010). By 
analysing the peripheral blood mononuclear cells (PBMCs), it was found that 






double negative (DN) T cells was expanded 
in patients with SLE when compared with those of rheumatoid arthritis (RA) 
and healthy individuals, and the expansion of the DN T cell population was 
demonstrated to cause an increase in the production of IL-4 in lupus patients 
(Dean et al. 2002). The elevated IL-4 level further exaggerates the production 
of autoantibodies because IL-4 is involved in the differentiation of naïve CD4
+ 
T cells into T helper type 2 (Th2) cells which function to induce antibody 
production from plasma cells (Zhu and Paul 2008). In addition to IL-4, another 
study demonstrated that the expanded DN T cells population in patients with 
SLE was capable of inducing the production of pro-inflammatory cytokines 
IL-17 and IFN-γ (Crispín et al. 2008). In the same study, kidney biopsies from 
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patients with lupus nephritis revealed increased expression of IL-17 and IL-23 
and infiltration of DN T cells in the tubule-interstitial zone (Crispín et al. 
2008). IL-17 augments inflammatory response by recruiting effector cells to 
target organs and increasing the survival and proliferation of B cells in the GC 
while IL-23 induces IFN-γ production from dendritic cells and promotes 
survival of Th17 and DN T cells (Crispín et al. 2010; Riol-Blanco et al. 2010). 
An early work reported an elevated subpopulation of γ/δ TCR-expressing DN 
T cells in patients with SLE and this subpopulation induced anti-DNA 
antibody production (Shivakumar et al. 1989). In addition, an abnormality in 
the TCR subunit has also been observed in patients with SLE (Liossis et al. 
1998). Under normal condition, T cell signalling is initiated by the 
engagement between MHC molecules expressed on APCs and TCR on T cells 
which subsequently activates the TCR associated protein kinase (ZAP70)-
calcium/calmodulin-dependent protein kinase type IV (CAMK4) signalling 
pathway (Liu and Davidson 2012). However, in SLE, the CD3-δ subunit of the 
TCR is substituted by the FcR-γ chain which instead triggers the spleen 
tyrosine kinase (Syk) signalling pathway (Liossis et al. 1998). As a result, the 
Syk signalling pathway leads to enhanced production of IL-17 but inhibition 





 T regulatory (Treg) cells, the lack of IL-2 may account 
for the loss of suppressive function of Treg in SLE patients (Malek 2003; 
Crispín et al. 2010).  
1.2.2 Impaired Apoptosis in SLE 
Cell death is a naturally occurring process which plays a critical 
homeostatic role in both physiological and pathological conditions in all 
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tissues and it is regulated by apoptosis or necrosis (Shao and Cohen 2011). 
Commonly known as premature cell death, necrosis is characterized by 
cytoplasmic and mitochondrial swelling and ultimately cellular membrane 
disruption that leads to cell lysis (Munoz et al. 2008). On the other hand, 
apoptosis is a programmed cell death mechanism that is induced by the 
extrinsic Fas-FasL signalling pathway or the intrinsic mitochondrial Bcl-2 
pathway (Salmon and Gordon 1999). Apoptotic cells undergo chromatin 
condensation, cytoplasmic contraction, and formation of apoptotic blebs which 
are systematically packaged into apoptotic bodies (Crispín et al. 2010). Under 
normal condition, apoptotic bodies are able to be recognized and cleared by 
phagocytic cells such as macrophages without globally activating the immune 
system (Crispín et al. 2010). However, the apoptotic and clearance processes 
are defective in SLE (Mok and Lau 2003). In a study analysing the lymph 
node biopsy specimens from patients with SLE and those without SLE but 
with hyperplasia and lymphoma, accumulation of apoptotic cells and defective 
phagocytosis were observed in the GCs of the lymph nodes in the former 
(Baumann et al. 2002). In another study of polymorphonuclear neutrophils 
(PMNs) and monocytes isolated from patients with SLE and healthy 
individuals, the proportions of apoptotic and secondary necrotic PMNs from 
SLE patients were found to be significantly higher than those from healthy 
controls (Ren et al. 2003). Furthermore, the same study also demonstrated that 
the phagocytic activity of macrophages was significantly reduced in SLE 
patients when compared with healthy controls. The phagocytic activity of 
macrophages from patients with SLE to clear apoptotic PMNs were shown to 
be negatively associated with the clinical SLE Disease Activity Index 
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(SLEDAI) and serum levels of anti-dsDNA but positively correlated with the 
serum levels of complements and albumin (Ren et al. 2003). High mobility 
group box protein 1 (HMGB1) is a DNA binding protein which binds and 
stabilizes the structure of nucleosomes (Urbonaviciute et al. 2008). HMGB1 
plays an essential role in facilitating cell transcription and repair but it triggers 
inflammatory responses when it is released to the extracellular environment 
during necrosis (Fiuza et al. 2003; Abdulahad et al. 2011). A recent study has 
demonstrated that the HMGB1-nucleosome complexes were detected in the 
plasma of patients with SLE and these complexes were capable of stimulating 
the secretion of IL-1β, IL-6, IL-10, and tumour necrosis factor (TNF)-α in 
macrophages and dendritic cells and inducing anti-dsDNA and anti-histone 
IgG responses in a TLR dependent pathway (Urbonaviciute et al. 2008). By 
using Western blot analysis, another study demonstrated that the serum 
HMGB1 levels in patients with SLE were significantly higher than those of 
healthy individuals and were positively associated with the SLEDAI, degree 
of proteinuria, and anti-dsDNA level (Abdulahad et al. 2011). Additionally, it 
was reported that the non-phagocytosed apoptotic cells undergo secondary 
necrosis which increased the release of HMGB1-nucelosome complexes in to 
the extracellular environment, thus further exacerbating pro-inflammatory 
immune response (Herrmann et al. 1998). Taken together, defective clearance 
of apoptotic bodies leads to the accumulation and amplification of danger 
signals that trigger the activation of both innate and adaptive immune 




1.3 A Review of adrenomedullin 
Adrenomedullin (ADM) is a novel peptide which was first identified 
by Kitamura et al in human phaeochromocytoma in 1993 (Kitamura et al. 
1993a). While monitoring the elevated activity of platelet cyclic adenosine 
monophosphate (cAMP) for biologically-active hypotensive peptides in 
human phaeochromocytoma, Kitamura et al discovered several unidentified 
minor bioactive peaks apart from those triggered by the known biologically 
active peptides; namely vasoactive intestinal peptide (VIP) and calcitonin gene 
related peptide (CGRP) which are potent vasodilators (Kitamura et al. 1993a).  
Subsequently, a peptide of a constant 52 amino-acid sequence was identified 
in one of the minor bioactive peaks and was then designated as 
“adrenomedullin” because it is found abundantly in normal adrenal medulla 










Fig. 1.3.1 Schematic diagram of the synthesis and structures of the human 
ADM (Cheung and Tang 2012). 
 
 
Human ADM gene is located on chromosome 11 which consists of 
four exons and three introns (Bełtowski and Jamroz 2004; Zudaire et al. 2006). 
It encodes for a 185 amino acid peptide named preproADM which is 
converted to proADM after the cleavage of the 21-residue N-terminal 
signalling peptide (Bełtowski and Jamroz 2004; Zudaire et al. 2006). ProADM 
acts as a precursor for mature ADM and another active peptide known as 
proadrenomedullin N-terminal 20-peptide (PAMP) (Bełtowski and Jamroz 
2004). ADM was postulated to be produced by a two-step enzymatic cleavage 
mechanism in which pro-ADM is processed to form a 53 amino-acid peptide 
of an intermediate form (I-ADM) (Bełtowski and Jamroz 2004; Kitamura et al. 
1998). I-ADM is subsequently converted to the 52 amino-acid bioactive 
mature form (mADM) by enzymatic amidation (Kitamura et al. 1998). As 
depicted in Fig 1.3.1, the ADM molecule consists of a 6-amino acids ring 
formed by an intramolecular disulphide bridge between residues 16 and 21 
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and an amidated tyrosine at the carboxyl terminus (Bełtowski and Jamroz 
2004; Kuwasako et al. 2011). Both of these structures are important for its 
biological functions such as receptor binding and downstream signalling 
(Bełtowski and Jamroz 2004). The structure of ADM shares some degree of 
homology with that of the CGRP, calcitonin and amylin (Kitamura et al. 
1993a; Bełtowski and Jamroz 2004). Unlike human ADM, rat and mouse 
mature ADM only consists of 50 amino acids that lacks 2 residues on their N-
termini and six of the residues are substituted (Bełtowski and Jamroz 2004; 
Kuwasako et al. 2011). However, the six amino acids ring structure and 
amidated carboxyl terminus are conserved in these species (Kuwasako et al. 
2011).  
While ADM is rich in phaeochromocytoma, this peptide is also 
abundant in other tissues with its distribution varies in different species (Ichiki 
et al. 1994). In human, radioimmunoassay (RIA) for ADM revealed that its 
immunoreactivity was the highest in adrenal medulla, followed by that in the 
plasma, heart atrium and pancreas (Ichiki et al. 1994). Another study using 
Northern blot analysis on the messenger RNA (mRNA) of human ADM found 
that ADM was also detectable in the heart, kidney and lung besides adrenal 
medulla (Kitamura et al. 1993b). On the other hand, in mice and rats, the 
expression of ADM mRNA was found to be highest in uterine epithelium and 
adrenal medulla using in situ hybridization (Cameron and Fleming 1998). In 
the same study, moderate levels of ADM mRNA were detected in kidney 
(glomerulus and cortical distal tubules), ovarian corpus luteum and follicles, 
lung, and cardiac muscles (Cameron and Fleming 1998). The localization of 
ADM in the aforementioned peripheral tissues suggests its possible function as 
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a circulating hormone participating in cardiovascular homeostasis. Besides, 
ADM was shown to be secreted by some cell types in vitro, including 
macrophage, cultured endothelial cells and vascular smooth muscle cells 
(VSMC) (Sugo et al. 1994; Kubo et al. 1998).  
The biological effect of ADM is mainly mediated by two G-protein 
coupled receptors, namely CGRP1 receptor and ADM receptor (Bełtowski and 
Jamroz 2004). These receptors consist of two molecules:  a calcitonin 
receptor-like receptor (CLR) receptor and an accessory protein known as 
receptor activity-modifying proteins (RAMP) (Geissler et al. 2010).  RAMP1 
is associated with CLR to form CGRP1 receptor while RAMP2 and RAMP3 
are coupled to CLR to form ADM1 and ADM2 receptors respectively (Geissler 
et al. 2010; Bełtowski and Jamroz 2004). The distribution of CLR is found 
ubiquitously in rat lung and vascular endothelial cells (Bełtowski and Jamroz 
2004). The three subtypes of RAMPs, however, are expressed in different 
tissues in human, rat and mouse (Kitamura et al. 2002). RAMP1 is found 
abundantly in the brain, fat, thymus and spleen; RAMP2 in found in the lung, 
spleen, fat and aorta while RAMP3 is found in the kidney and lung (Kitamura 
et al. 2002).  
Though the exact physiological role of ADM in human remains to be 
explored, studies have unanimously confirmed that ADM is a potent 
vasodilator (Kitamura et al. 1993a; Brain et al. 1985) . In anaesthetized rats, 
intravenous administration of 3mmol/kg of ADM caused a mean blood 
pressure drop of 53mmHg and this significant effect lasted for up to 60 
minutes (Kitamura et al. 1993a). This prompt, powerful and long lasting 
hypotensive effect was comparable to that of CGRP which had been 
13 
 
established as one of the strongest vasodilators (Brain et al. 1985).  Through 
the CGRP1 receptors on the VSMC and endothelial cells, ADM was capable 
of increasing intracellular cAMP in the former and inducing nitric oxide (NO) 
release in the latter (Ichiki et al. 1994). This results in lowering peripheral 
vascular resistance and subsequently the systemic blood pressure (Kitamura et 
al. 1993a).  
While investigators are eager to elucidate the possible physiological 
role and behaviour of ADM, correlation studies showed that plasma level of 
ADM was elevated in certain disease conditions. Ishimitsu et al demonstrated 
that plasma ADM levels in patients with essential hypertension and chronic 
renal failure were significantly higher than those in normal subjects (Ishimitsu 
et al. 1994).  In patients with chronic idiopathic glomerulonephritis and IgA 
nephropathy, increased plasma ADM levels were reported in several studies 
(Kinoshita et al. 2000; Nitta et al. 2000). Recently, total ADM level was also 
found to be significantly higher in individuals with type II diabetes mellitus 
and chronic periodontitis when compared with the other groups (diabetes 
mellitus type II and periodontally healthy individuals, periodontally healthy 
individuals and individuals with chronic periodontitis) (Ertugrul et al. 2012). 
In another  study using quantitative reverse-transcriptase polymerase chain 
reaction (RT-PCR) and immunohistochemistry (IHC), the levels of ADM 
mRNA and protein were determined to be elevated in human pancreatic 
cancer samples when compared with healthy controls (Aggarwal et al. 2012).  
In animal models, cardiovascular stress caused by aortic constriction or 
angiotensin II infusion resulted in more prominent renal damage, left 
ventricular wall thickness, perivascular fibrosis and decreased renal creatinine 
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 mice showed pronounced enhancement of extracellular signal-
regulated kinase (ERK) activation in cardiac myocytes when subjected to 
aortic constriction (Niu et al. 2004).  Niu et al also revealed that the treatment 
with recombinant ADM suppressed angiotensin II-induced ERK activation via 
a protein kinase (PK) A-dependent pathway (Niu et al. 2004). Since ERK has 
been known to play a key role in the development of cardiac hypertrophy, 
inhibition of ERK may relieve cardiomyopathy (Indolfi et al. 2002). In another 
study using Dahl salt-sensitive rats, chronic recombinant human ADM 
treatment significantly inhibited the increase in plasma renin concentration by 
269%, aldosterone level by 82%, angiotensin II level by 60% and the 
treatment improved their renal function, urine protein excretion and 
histological glomerular injury score (Nishikimi et al. 2002).  A recent study 
examined the effect of ADM on kidney injury induced by infrarenal 
abdominal aortic ischemia-reperfusion (IR) in Wistar-Albino rats (Oyar et al. 
2012). In this study, ADM treatment was found to significantly decrease the 
tissue and plasma levels of malondialdehyde, superoxide dismutase, catalase, 
myeloperoxidase, IL-1β, blood urea nitrogen (BUN), and Cr compared with 
the non-treated IR group (Oyar et al. 2012). In addition, immunohistological 
study demonstrated that the caspase-3 immunoreactivity was lower in cortex 
and medulla in the ADM treated IR group (Oyar et al. 2012).  
Taken together the aforementioned results, it is reasonable to postulate 
that ADM plays a homeostatically important compensatory role in 
hypertension and renal failure. ADM unequivocally exerts its renoprotective 
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and cardioprotective effects via manipulation of the intracellular signalling 
pathway, predominantly the PKA pathway.  
1.4 ADM and the immune system 
Over the past two decades, more evidence has suggested that ADM has 
an intimate relationship with the immune system. Using RIA and RNA blot 
analysis, Sugo et al demonstrated that the production of ADM was augmented 
by the pro-inflammatory cytokines including IL-1α, IL-1β, TNF-α, TNF-β, 
and lipopolysaccharide (LPS) in cultured rat VSMC (Sugo et al. 1995). 
Amongst the cytokines, IL-1α and IL-1β were ten times more potent than that 
of TNF-α and TNF-β in stimulating ADM production in VSMC (Sugo et al., 
1995). In a later study using cultured murine monocyte/macrophage cell line, 
Kubo et al attempted to identify the effects of various substances on the 
differentiation and activation of monocyte/macrophage (Kubo et al. 1998).  It 
was found that phorbol ester, retinoic acid, LPS, and IFN-γ increased ADM 
production by up to seven times in the cultured macrophages in a dose and 
time dependent manner (Kubo et al. 1998). On the other hand, glucorcoticoids 
and transforming growth factor-beta (TGF-β) suppressed ADM production in 
macrophages in a dose dependent fashion (Kubo et al. 1998). Using mouse 
peritoneal macrophage cell lines, ADM administration was found to suppress 
the secretion of TNF-α and IL-6 from those stimulated with LPS (Kubo et al. 
1998). In the settings of sepsis and inflammation (and probably 
atherosclerosis), the augmentation of ADM production in macrophages is 
deduced to function as a modulator of cytokine production (Bełtowski and 
Jamroz 2004). Furthermore, the concerted effect of ADM and NO on 
relaxation of VSMC subsequently gives rise to vasodilation characterized by 
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extravasation, oedema, hypotension and shock (Sugo et al. 1994).  
During the acute phase of infection, neutrophils are amongst the first 
inflammatory cells to migrate towards the vicinity of inflammation (Saito et al. 
2001). ADM was reported to be secreted by neutrophils and it was capable of 
potentiating the accumulation of neutrophils via an IL-1β-dependent 
mechanism, resulting in the formation of inflammatory oedema (Saito et al. 
2001). In the context of ischemic brain injury, however, ADM was proposed to 
have a potential inhibitory effect on the activation and migration of 
neutrophils because it suppressed formyl-Met-Leu-Phe-induced upregulation 
of the adhesion molecule CD11b (Saito et al. 2001; Watanabe et al. 2001). In 
addition, ADM has been demonstrated to be secreted by Swiss 3T3 fibroblasts 
(Isumi et al. 1998). Similar to the rat VSMC and endothelial cells, the 
secretion of ADM from the Swiss 3T3 fibroblast was elevated by TNF-α, IL-
1β, dexamethasone but suppressed by TGF-β1 and IFN-γ (Isumi et al. 1998). 
Furthermore, the secreted ADM was also demonstrated to increase cAMP 
production and DNA synthesis in the fibroblasts and these effects could be 
inhibited by a monoclonal antibody against the carboxyl-terminal fragment of 
ADM (Isumi et al. 1998). These results suggested that ADM may act as a local 
regulator during inflammation. In a recent study using bleomycin (BLM)-
induced lung injury CD-1 mice model, ADM decreased myeloperoxidase  
activity, cytokines (TNF, IL-1β), adhesion molecules (ICAM-1 and P-
selectin), TGF-β and NO synthase expression when compared to BLM-
induced vehicle group (Di Paola et al. 2011). The author concluded that ADM 
could prevent BLM-induced lung injury by down-regulating the pro-
inflammatory factors (Di Paola et al. 2011). Taken together, these reports 
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strongly suggested that ADM peptide is closely associated with the immune 
system and it is capable of modulating the immune response through the 
regulation of inflammatory markers.  
1.5 The Association between ADM and SLE 
The relationship between ADM and SLE has been addressed in a few 
studies. Plasma ADM was shown to be elevated in SLE patients when 
compared with healthy controls in a cross-sectional study of 47 consecutive 
patients with SLE (Cheung et al. 2000). Moreover, the plasma ADM level in 
SLE patients was significantly associated with SLE disease activity in terms of 
anti-dsDNA antibody level and the SLEDAI (Cheung et al. 2000). In patients 
with active disease, the plasma ADM levels tended to be lower in those who 
were on immunosuppressive therapy (prednisolone, azathioprine and 
cyclophosphamide) than those who were not (Cheung et al. 2000). This study 
underscores the potential importance of ADM in the pathogenesis of SLE 
(Cheung et al. 2000). By using RT-PCR, Nishitani et al demonstrated that 
patients with SLE had elevated IL-6 mRNA level in PBMC whereas that of 
ADM was suppressed when compared with healthy controls (Nishitani et al. 
2001). IL-6 mRNA levels in PBMC had positive association with the 
SLEDAI, BUN, serum Cr, 50% haemolytic unit of complement and 24-hour 
protein excretion in urine (Nishitani et al. 2001). On the contrary, ADM 
mRNA levels in PBMC showed negative correlation with those parameters as 
well as anti-dsDNA antibody titre (Nishitani et al. 2001). However, there was 
no correlation observed between IL-6 mRNA level and anti-dsDNA antibody 
level (Nishitani et al. 2001). In a more recent study using RIA and renal 
histopathology, plasma ADM level was also reported to be significantly higher 
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in SLE patients as well as SLE patients with nephritis when compared with 
normal controls and SLE patients without nephritis (Mak et al. 2006). In this 
study, the SLEDAI was shown to be positively associated with plasma ADM 
after multivariate adjustment in the regression analysis (Mak et al. 2006). This 
result further supported the previous findings by Cheung et al who showed 
that plasma ADM was significantly correlated with the SLEDAI (Cheung et al. 
2000). It is also believed that the elevation of plasma ADM level is a 
consequence rather than a cause of the pathology (Cheung et al. 2000).  
1.5 ADM and glomerulonephritis 
Experimental studies in cultured rat glomerular mesangial cells (MCs), 
anti-Thy-1.1 antibody induced rat glomerulonephritis (GN) model and clinical 
studies in IgA nephropathy shed some light on the anti-inflammatory role of 
ADM on GN. An early experimental work by Kohno et al found that ADM 
increased the cAMP level in cultured rat MCs (Kohno et al. 1995). In a 
subsequent study, ADM demonstrated a dose-dependent anti-proliferative 
effect on cultured rat MCs by inhibiting the platelet-derived growth factor 
(PDGF) and angiotensin II induced migration and proliferation (Kohno et al. 
1999). This inhibition was proposed to be mediated by specific ADM 
receptors coupled with CGRP interaction, through cAMP-dependent 
mechanisms (Kohno et al. 1999). In another study, the localization of ADM 
was confirmed in the mesangial and microvascular areas of rat glomeruli by 
IHC (Chini et al. 1997). It is reported that the synthesis of ADM in cultured 
MCs was stimulated by TNF-α and IL-1β but not by PDGF and vascular 
endothelial growth factor (VEGF) (Chini et al. 1997). ADM was able to 
inhibit the generation of reactive oxygen species (ROS) in MCs and caused 
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activation of PKA (Chini 1997). In the same study, when using [3H]-
incorporation to measure the rate of proliferation, the activity of mitogen-
activated protein kinase (MAPK) stimulated by PDGF and EGF were 
suppressed by ADM in a concentration-dependent manner (Chini et al. 1997). 
These results collectively indicated that the suppression of ADM on the 
proliferation of rat glomerular MCs is mediated by the cAMP-induced PKA 
mechanism, leading to inhibition of the MAPK signalling pathway (Chini et 
al. 1997). In a more recent work, ADM treatment was shown to reduce MCs 
proliferation, glomerular monocyte infiltration and inflammation in anti-Thy-
1.1 antibody induced rat GN (Plank et al. 2005). The role of ADM in GN was 
further examined in the study by Geissler et al using the same anti-Thy-1.1 
antibody induced rat GN model (Geissler et al. 2010). In GN, the mRNA 
expressions of ADM, CLR, RAMP2 and RAMP3 were shown to be 
downregulated (Geissler et al. 2010). Exogenous administration of ADM via 
subcutaneous injection was reported to increase the expression of ADM but 
not its receptors (Geissler et al. 2010). In short, these results indicated that 
ADM generated in MCs can suppress ROS generation in MCs, infiltrating 
macrophages as well as MAPK-mediated mitogenesis in MC. Thus, it was 
suggested that ADM may act as a local cytoprotective peptide that suppresses 
pathological processes evoked by immuno-inflammatory injury of glomeruli 
(Geissler et al. 2010).  
In the clinical study of IgA nephropathy, Kubo et al demonstrated that 
ADM mRNA level in PBMC of patients with IgA nephropathy tended to be 
lower when compared with healthy subjects (Kubo et al. 2000). Subgroup 
analysis showed that ADM mRNA levels were significantly lower in patients 
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with histologically severe IgA nephropathy than that in patients with mild-
grade nephritis (Kubo et al. 2000). In addition to this finding, Kubo et al 
reported a correlation between ADM mRNA and C-type natriuretic peptide 
(CNP) mRNA levels in the PBMC of patients with IgA nephropathy in which 
the latter peptide was previously reported to inhibit rat MCs proliferation 
(Kubo et al. 2000; Canaan-Kühl et al. 1998). It was therefore postulated that 
the downregulation of ADM and CNP may promote the proliferation of MC in 
patients with IgA nephropathy (Kubo et al. 2000).  
With the in vitro and in vivo findings on glomerulonephritis as well as 
clinical observation in IgA nephropathy, it is intriguing to examine whether 
ADM exerts the same behaviour and relationship with glomerular cells in 
lupus nephritis. Since its discovery till now, there were only very few studies 
in the literature which addressed the relationship between ADM and lupus 
nephritis. As discussed earlier, patients who had active nephritis was shown to 
have higher IL-6 mRNA and reduced ADM mRNA expression in PBMC 
compared with those who had inactive nephritis (Nishitani et al. 2001).  
Furthermore, the level of IL-6 mRNA expression in active lupus patients was 
negatively correlated with ADM expression. Upon immunosuppressive 
treatment, expression of ADM increased whereas that of IL-6 was suppressed 
(Nishitani et al. 2001). The author therefore postulated that ADM possesses an 
anti-inflammatory role in patients with SLE and it may be a potential disease 
activity marker for SLE (Nishitani et al. 2001). In a more recent study, 
proteinuria was found to be negatively correlated with plasma ADM level by 
regression analysis (Mak et al. 2006). This finding intrigued the author to 
propose a possible mechanism of ADM in the pathogenesis of SLE nephritis. 
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In SLE, the manifestation of increased pro-inflammatory cytokines such as 
TNF-α, IL-1β and IFN-γ induces ADM secretion by macrophages, 
lymphocytes and endothelium (Mak et al. 2006). The secreted ADM was 
believed to exert its anti-proliferative effect on the kidney glomerular and 
MCs and thus reducing proteinuria, which is an indicator of nephritis activity 
(Mak et al. 2006). 
To date, studies aiming to examine the relationship between plasma 
ADM, SLE and lupus nephritis are scant. It prompts the present study to 
investigate the immunological role of ADM on lupus-related kidney 

























(MRL/lpr) mice offer a well-established murine model 
for researchers to study the pathogenesis of SLE as the animals exhibit 
comparable phenotypic and immunological features as those observed in 
human patients with SLE (Alexander et al. 2007). These mice carry 
homozygous Fas mutation which renders them spontaneously develop lupus-





start to develop signs of lupus-like disease as early as 8 
weeks of age (Wenderfer et al. 2009). Studies have shown that the MRL/lpr
 
mice have a mortality rate of 50% after 20 weeks and that of 90% after 30 
weeks (Izui et al. 1984; Reilly and Gielkeson 2002). Being the second most 
common manifestation in patients with SLE, skin disease is also commonly 
observed in the MRL/lpr mice (Deng et al. 2010). Skin lesions accompanied 
by hair loss and scab formation are common at about 12 weeks’ old while 
erythematous lesions of the ear often become necrotic after the age of 24 
weeks (Reilly et al. 2006). Starting at about 12 weeks of age, levels of a 
number of circulating autoantibodies increase significantly in the homozygous 
lpr mice (Reilly and Gielkeson 2002). The array of autoantibodies produced in 
these mice is similar to those observed in human SLE patients, such as the 
anti-dsDNA antibody (Reilly and Gielkeson 2002). At the age of 4 to 5 
months, these mice develop immune-complex induced pathology including 
GN, arthritis and vasculitis, in addition to massive lymphadenopathy and 
splenomegaly (Bettinardi and Brugnoni 1997). Immunopathology such as full-
house deposition of IgA, IgG, IgM, C3 and C1q in the glomeruli as well as 
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glomerular crescent formation renders this mouse model an ideal asset to be 
used in studying the pathogenesis and testing potential therapeutics in SLE. 
1.6.2 Genetics of MRL/ Fas
lpr
 mice 
Located on chromosome 19 in mice, the Fas gene is involved in the 
apoptosis signalling which plays a key role in cellular homeostasis in the 
immune system (Watanabe-Fukunaga et al. 1992). The receptor, Fas/Apo-1 
(CD95) is a membrane bound receptor protein with a single transmembrane 
domain (Bhandoola et al. 1994). Fas belongs to the tumour necrosis 
factor/nerve growth factor (TNF/NGF) cytokine receptor family and it is 
widely expressed in the thymus, liver, heart, lung, kidney, and ovary (Wallach 
et al. 1999). The activity of Fas is governed by the interaction with its ligand 
(FasL), which is expressed on the surface of activated cytotoxic T-cells as well 
as some activated Th1 cells (Bettinardi and Brugnoni 1997). Cross-linking of 
Fas with cells expressing FasL or with purified soluble FasL activates caspase 
8 (Bettinardi and Brugnoni 1997). This subsequently leads to condensation of 
chromatin, fragmentation of the nucleus and the chromosomal DNA of target 
cells, which are characteristic features of the apoptotic cell death mechanism 
(Bettinardi and Brugnoni 1997; Bouchier-Hayes et al. 2010). This mechanism 
is important in both the thymus and in the periphery, where it functions to 
eliminate autoreactive lymphoid cells and to clear activated-lymphocytes that 
responded to foreign antigens (Bhandoola et al. 1994).  
lpr (lymphoproliferation) mutation is autosomal recessive and the  
locus of lpr gene has been found to be adjacent to the Fas gene during 
chromosome mapping (Watanabe-Fukunaga et al. 1992). In lpr mice, an early 
transposable element is inserted in intron 2 of Fas gene, causing alternative 
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splicing of the Fas gene that leads to aberrant, non-functional transcripts 
(Adachi et al. 1993). In mice carrying homozygous lpr mutation, low level of 
Fas antigen mRNA was detected in the thymus and liver (Watanabe-Fukunaga 
et al. 1992; Reilly and Gielkeson 2002). This deficiency subsequently results 





 T cells due to the failure of proper clearance of the DN T 
cells (Watanabe-Fukunaga et al. 1992; Gu et al. 1998). In contrast, MRL/MpJ 
mice which lack the lpr mutation develop a much later onset of autoimmune 
disease, lower levels of circulating immune complexes and less severe 
proliferative GN as compared with the MRL/lpr mice (Gu et al. 1998). This 
suggests that the lpr gene is involved in the magnification and acceleration of 
the lupus-like disease. (Hahn 2001). 
1.6.3 Immunopathogenesis of MRL/Fas
lpr
 mice 
 SLE symptoms attributed to Fas deficiency in MRL/lpr mice are 
dependent on both CD4
+
 T cells and B cells (Jabs et al. 1994). In normal 
situation, high levels of Fas are expressed on T and B cells upon activation 
(Reap et al. 1995). However, splenic T cells extracted from lpr mice that were 
7- to 12- months old were shown to have less apoptosis than MRL/MpJ T cells 
by cell culture (Reap et al. 1995). In another study, the non-autoimmune 
C3H/HeJ and C57BL/6J strains were shown to develop lymphoproliferation 
and had a reduced lifespan with the presence of the lpr mutation (Izui et al. 
1984). This indicated that the defect in apoptosis is mainly due to the lack of 
functional Fas receptor on T cells (Perry et al. 2011).   
In addition to T cells, loss of B cell tolerance contributes to the 
formation of autoantibodies and spontaneous T cells activation in the MRL/lpr 
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mice (Chan et al. 1999). In the MRL/lpr mice, hyperreactive B cells present 
autoantigens, induce Th cells and inhibit Treg cells via an upregulated 
expression of MHC class II molecules on their surfaces (Tsubata 2005). This 
does not only provide co-stimulatory signals necessary for T cell activation, 
differentiation and expansion but also enhances the expansion of autoreactive 
B cells and leads to the overexpression of circulating autoantibodies (Tsubata 
2005). Additionally, there is also overexpression of CD40L on B cells which 
causes excessive T cell co-stimulation and subsequently results in 
immunoglobulin class switching (Hostmann et al. 2008). In the MRL/lpr mice, 
B cells also produce pro-inflammatory cytokines like IL-10, IL-16, TNF-α, 
and IFN-γ (Dörner et al. 2011).  
One of the hallmarks of glomerulonephritis is the proliferation of 
glomerular MCs and the infiltration of macrophages/ monocytes into the 
glomeruli during the onset of nephritis (Reilly and Gielkeson 2002). 
Macrophages derived from glomeruli of the MRL/lpr mice exhibited elevated 
secretion of NO, TNF-α, and IL-1β (Reilly and Gielkeson 2002).  Similarly, 
MCs isolated from the MRL/lpr mice generated higher expression of TNF-α, 
IL-6, IL-12 and NO when stimulated by pro-inflammatory chemokines and 
cytokines (Aringer and Smolen 2005). Acting as an inflammatory mediator, 
NO inhibits cell function by generating highly reactive and toxic hydroxyl 
radical when reacts with O2 radicals (Reilly and Gielkeson 2002). Renal 
histology of the MRL/lpr mice also showed glomerular deposition of immune 
complexes including IgG, C3 and C1q complement (Shimp et al. 2012). The 
cytokines and chemokines which are induced by immune complexes and 
secreted by infiltrating macrophages further promote the migration of other 
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inflammatory cells which in turn produce pro-fibrotic cytokines, resulting in 
excessive accumulation of extracellular matrix and renal fibrosis (Tan et al. 
2012).  
The extensive production of anti-DNA antibodies in the MRL/lpr mice 
is reported to be correlated with lupus glomerulonephritis (Gu et al. 1998). 
Due to the dysregulation in Fas-dependent apoptosis, decreased clearance of 
apoptotic bodies results in elevated circulating dsDNA fragments and 
nucleosomes in the serum (Berden et al. 1999). These apoptotic bodies act as 
autoantigens for autoreactive B cells which generate anti-nuclear antibodies 
such as the anti-dsDNA antibody (Clatworthy and Smith 2007).  Together 
with other autoantibodies, the anti-dsDNA antibodies form immune 
complexes with the autoantigens and deposit in the glomeruli which induce 
inflammation and tissue injury (Mevorach et al. 1998).  
 In summary, the MRL/lpr mice were selected as a lupus murine model 
in this study due to the aforementioned characteristics and immunopathology 








1.7 Aims and Objectives 
This project aimed to understand the immunological role of ADM on 
lupus-related kidney inflammation and to explore ADM as a potential 
immune-modulating agent for alleviating lupus-related kidney inflammation. 
The following research questions will be investigated:  
1. To examine the effect of ADM on the phenotype, disease progression 
and glomerular deposition of immune complexes, complements and 
immunoglobulins of the MRL/lpr mice.  
2. To evaluate the impact of exogenous ADM on the splenocytes of the 













CHAPTER 2 MATERIALS AND METHOD 
2.1 Reagents  
0.9% Sodium Chloride solution, saline was from B Braun, Germany; 5(6)-
carboxyfluorescein diacetate N-succinimidyl ester (CFSE) was from Sigma-
Aldrich, USA; ADM peptide was from Biomatik, USA; Alexa Fluor 488-
conjugated anti-IgG was from Invitrogen, USA; Alexa Fluor 488 conjugated 
IgM was from Invitrogen, USA; Alexa Fluor 700-conjugated anti-B220 was 
from eBioscience, USA; Alexa Fluor Donkey anti-Rabbit 546-conjugated IgG 
was from Invitrogen, USA; Alexa Fluor Goat anti-mouse 488-conjugated IgM 
was from Invitrogen, USA; Alexa Fluor Rabbit anti-mouse 488-conjugated 
anti-IgG was from Invitrogen, USA; Allophycocyanin (APC)-conjugated anti-
B220 was from BD Pharmingen, USA; Ammonium-Chloride-Potassium 
(ACK) lysis buffer was from Lonza, Switzerland;  APC-conjugated Annexin 
V was from BD Pharmingen, USA; APCCy7-conjugated anti-CD11b was 
from eBioscience, USA; APCCy7-conjugated anti-CD69 was from 
eBioscience, USA; AtheNA Multi-Lyte® ANA-III Plus Test System was from 
Zeus Scientific Inc, USA; B Cell Isolation kit was from Miltenyi Biotec, 
Germany; Brilliant Violet (BV) conjugated anti-CD8 was from eBioscience, 
USA; Anti-CD3/CD28 monoclonal antibody was from Biolegend, USA; 
CpGb oligodeoxynucleotides was from Invitrogen, USA; Donkey anti-mouse  
IgG was from Jackson ImmunoResearch, USA; FcR Blocking Reagent (mouse) 
was from Miltenyi Biotec, Germany; Fetal Bovine Serum (FBS) was from 
Life Technologies, USA; Fluorescein isothiocyanate (FITC)-conjugated anti-
IgA was from Invitrogen, USA; FITC-conjugated anti-CD45 was from BD 
Pharmingen, USA; MACS buffer - 2mM EDTA in 1x Phosphate buffered 
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saline (PBS); Mouse monoclonal IgG anti-C3 was from Santa Cruz, USA; 
Mouse monoclonal IgM anti-dsDNA was from Novus, USA; MRL/Fas
lpr 
mice 
were from The Jackson Laboratory, USA; Pacific Blue (PB) -conjugated anti-
CD3 was from eBioscience, USA; Pacific Orange (PO)-conjugated anti-CD45 
was from eBioscience, USA; PECy5-conjugated anti-7-Amino-actinomycin D 
(7-AAD) was from BD Pharmingen, USA; PECy7-conjugated anti-CD8 was 
from eBioscience, USA; Phycoerythrin (PE)-conjugated anti-CD4 was from 
eBioscience, USA;  Prednisolone tablets (5mg) was purchased from NUH 
Pharmacy; Rabbit monoclonal IgG anti-C1q was from Santa Cruz, USA; 
RPMI 1640 medium was from Sigma-Aldrich, USA; Shandon M-1 
embedding Matrix was from Thermoscientific, USA. 
2.2 Instruments and Software 
IBM SPSS Statistic version 20 was from IBM, USA; ImageJ software was 
from National Institutes of Health (http://rsbweb.nih.gov/ij); FACS Aria III 
cell sorter was from BD Biosciences, USA; Flow Cytometry BD LSR II was 
from BD Biosciences, USA; FlowJo software version 7.6 was from Tree Star, 
USA; Luminex® 100/200™ System was from Luminex, USA; Magnetic 
acitivated cell sorting (MACS) was from Miltenyi Biotec, Germany; Siemens 






2.3 Methods of Study  
2.3.1 Mouse model 
The MRL/Fas
lpr 
mice were purchased from The Jackson Laboratory 
and were bred and maintained at the vivarium of the Comparative Medicine of 
NUS. The mice were treated in accordance with the NUS Institutional Animal 
Care and Use Committee (IACUC). All experiments were only conducted in 
the female mice. The animals were housed in ventilated cages, at room 
temperature of 24 + 2 ºC and a humidity of 60 + 10% with a 12-hour 
light/dark cycle. The mice were fed on pelleted rodent diet and water was 
provided ad libitum. 
2.3.2 Treatment groups 
2.3.2.1 Early Intervention Group 
To examine the potential effects of exogenously administered ADM on the 
MRL/Fas
lpr 
mice with regard to the phenotypes and distribution of their 
splenic immunocytes as well as the severity of nephritis before the onset of the 
disease, 6-week old MRL/Fas
lpr 
mice from the ADM group (n =8) received 
ADM administered via intraperitoneal (IP) injection three times per week 
through the right lower quadrant of the abdomen (27µg in 0.2ml of normal 
saline [NS]) for a total period of 18 weeks. Similarly, the same age of the 
MRL/Fas
lpr 
mice from the control group (n=8) received (0.2ml) NS by IP 
injection of the same frequency for the same treatment duration as the ADM-
treated group.  
31 
 
2.3.2.2 Late Intervention Group 
To explore the potential inhibitory effect of exogenous ADM in the 
progression of kidney disease and to observe the impact of ADM on the 
phenotypic feature and distribution of splenic immunocytes after the onset of 
lupus-like disease, the MRL/Fas
lpr
 mice started receiving repeated IP injection 
of ADM (27µg in 0.2ml of normal saline), prednisolone (1mg/kg every in 
0.2ml normal saline) and NS (0.2ml) at the age of 12-week old thrice weekly 
for a total period of 6 weeks. The number of mice in each group was 7.   
2.3.3 Blood collection and serological analysis 
After the mice were euthanized at the age of 18- or 24-week old, the 
peripheral blood was collected by cardiac puncture. The blood was centrifuged 
at 13,200 rpm for 10 minutes to obtain the sera which were stored at -80°C 
until retrieval for immunoassays. The serum levels of a number of 
autoantibodies including anti-dsDNA, anti-Smith (Sm), anti-ribosomal P 
(RibP), anti-SSA 52 and anti-SSA 60 were determined using AtheNA Multi-
Lyte® ANA-III Plus Test System according to manufacturer’s instruction. 
Since the kit detects the above mentioned autoantibodies in human serum, a 
donkey anti-mouse IgG detection antibody was used to replace the PE- 
conjugated goat anti-human IgG antibody. In brief, the mouse sera were 
diluted in 1:21 with sample diluent provided in the kit. Ten µL of the diluted 
samples were mixed with 50 µL of bead suspension in a 96-well filtration 
plate and incubated for 30 minutes at room temperature. After incubation and 
washing, 150 µL of the conjugate detection antibody was added and the 
mixture was incubated for another 30 minutes at room temperature. The 
samples were then measured by using the Luminex® 200™ System with a 
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reporter laser at 532nm.  Samples with >120 IU/mL for anti-dsDNA and >120 
AU/mL for the other aforementioned autoantibodies were considered as 
positive.   
2.3.4 Measurement of the levels of protein and red blood cells in the urine  
Urine was collected one day before the animals were sacrificed and 
tested for the levels of protein and red blood cells by a standard 
semiquantitative test using Siemens Multistix 8 SG dipsticks. Results were 
quantified according to the manufacturer’s instructions and the scores are as 
follows: 
Proteinuria: 0mg/dL = 0, 30mg/dL= 1, 100mg/dL = 2, 300mg/dL 
=3, >2000mg/dL = 4. Hematuria: 0 cells/µL= 0, 10 cells/µL = trace, 25 
cells/µL = small, 80 cells/µL= moderate, 200 cells/µL= large.  
2.3.5 Preparation of single-cell suspensions of splenocytes, flow cytometry 
and fluorescent activated cell sorting (FACS) 
At the time of sacrifice, the mice were weighed before their spleens, 
cervical and axillary lymph nodes and kidneys were harvested. The lymph 
nodes and spleens were then weighed after they were harvested. The harvested 
spleens were then aseptically homogenized in MACS buffer to get single cell 
suspensions by using the mashing method. Briefly, the spleens were placed in 
petri dishes, immersed in 1-2mL MACS buffer and homogenized by using the 
plungers of 3mL syringes. The homogenized cell suspension was then filtered 




During staining, the cells were enriched with a cocktail of biotin-
conjugated antibodies against CD43 (Ly-48), CD4 (L3T4), and Ter-119 as 
well as anti-biotin microBeads from the B Cell Isolation kit and were 





















 cells. For the B220
-
 
fraction, after being treated with ACK lysing buffer (NH4Cl 8,024 mg/L; 
KHCO3 1,001 mg/L  EDTA·Na2·2H2O 3.722 mg/L), it was then stained with 
monoclonal antibodies including FITC-conjugated anti-CD45, APC-
conjugated anti-B220, PE-conjugated anti-CD4, PECy5-conjugated anti-7-
AAD, PB-conjugated anti-CD3, PECy7-conjugated anti-CD8, and APC-Cy7-
conjugated anti-CD11b. The stained B220
-
 cells were then separated by the 



















 cells.  
The B220
+
 fraction was stained with monoclonal antibodies of FITC-
conjugated anti-CD45, APC-conjugated anti-B220, PB-conjugated anti-CD3, 
and APC-Cy7-conjugated anti-CD11b. Flow cytometric analysis was 
performed by using the BD LSR II and flow data were analysed by the FlowJo 
software version 7.6.1. 
2.3.6 Histological studies of kidneys 
2.3.6.1 Cryosection and fluorescent microscopy  
The kidneys extracted were embedded in Shandon M-1 embedding 
Matrix and frozen with dry ice and stored in -80
0
C until retrieval for 
histological studies. The frozen kidneys were cut into 6 µm cryosections and 
stained for primary antibodies comprising anti-C3 (1:100), anti-C1q (1:100) 
and anti-dsDNA (1:200) overnight followed by secondary antibodies of Alexa 
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Fluor Rabbit anti-mouse 488-conjugated anti-IgG (1:200), Alexa Fluor 
Donkey anti-mouse 546- conjugated IgG (1:200) and Alexa Fluor Goat anti-
mouse 488-conjugated IgM (1:200) respectively. In addition, the cryosections 
were also stained for Alexa Fluor 488-conjugated anti-IgG (1:200), Alexa 
Fluor 488-conjugated IgM (1:200) and FITC-conjugated anti-IgA (1:200) 
directly. The deposition of immune markers on the cortical regions was 
examined by fluorescent microscopy (Olympus) and the sections were 
compared among the different treatment groups under the same condition in 
terms of resolutions, exposure time, sensitivity and magnification. A minimum 
of three kidney sections from three mice in each group were examined. The 
mean fluorescence intensity (MFI) of the markers was quantitated using the 
ImageJ software. Briefly, the fluorescence intensity of each section was 
normalized with the respective background intensity and the mean of 
fluorescence intensity was obtained from three mice in each group.  
2.3.7 In vitro study of the impact of ADM on splenocytes 
Splenocytes were obtained from untreated MRL/lpr mice (12-14 weeks’ 
old) using the mashing method as described earlier in Section 2.3.5. The 
required number of cells were calculated by hemocytometer and resuspended 
in complete RPMI (cRPMI) medium (20 x 10
6
 cells/ ml cRPMI). An equal 
volume of diluted CFSE (1:4000 in plain RPMI) was added to the cell 
suspension and incubated for seven minutes in dark and at room temperature. 
This process was then stopped by adding an equal volume of fetal bovine 
serum (FBS) and incubated for one minute before proceeding to the washing 




cells was plated onto each well of a flat-bottom 
96-well plate. The labelled cells were then treated with CpGb oligonucleotide 
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and anti-CD3/CD28 monoclonal antibodies (with CD3 pre-coated overnight 
prior to the addition of cells); with or without stimulation with ADM 
(5µg/mL). The concentrations for the stimulants were as follows: CpGb- 0.5, 
0.1, 0.05 and 0.01 µM and anti-CD3/CD28- 1, 0.5, 0.1, 0.05 µg/mL. Cells 
were collected after 72hrs of culture for flow cytometric analysis. Prior to the 
staining, the cells were blocked by FcR blocking reagent to reduce non-
specific binding (1:5). The cells were enriched with the following antibodies: 
APCCy7-conjugated anti-CD69 (1:200), Alexa Fluor 700-conjugated anti-
B220 (1:200), PB-conjugated anti-CD3 (1:200) PE-conjugated anti-CD4 
(1:200), BV-conjugated anti-CD8 (1:200), PO-conjugated anti-CD45 (1:200) 
and PECy5-conjugated anti-7-AAD (1:20). APC-conjugated Annexin V was 
added to the stained cells and incubated for 15 minutes in dark and at room 
temperature. Flow cytometric analysis was performed by using BD LSR II and 
the flow data were analysed by the FlowJo software version 7.6.1.  
2.3.8 Statistical analyses 
Statistical analyses were carried out by using IBM SPSS Statistic 
version 20 software. The continuous variables were presented as mean ± SEM 
unless otherwise stated. Comparisons were made between the treatment and 
control groups using the student’s t-test or Mann-Whitney U test as 
appropriate for comparing between 2 groups and one-way ANOVA or 
Kruskal-Wallis test as appropriate for comparing between 3 groups. A 2-tailed 





CHAPTER 3 RESULTS 
3.1 ADM treatment significantly reduced lymphadenopathy  
 In both the early- and late intervention groups, the weight of the 
spleens and lymph nodes were found to be lower in the ADM treated group 
than those of their respective control groups. Although there was a trend of 
reduction in the average splenic mass of the ADM group when compared with 
the saline group but the difference was not statistically significant in the early 
intervention group (221.50±21.75 mg vs 428.60±21.75 mg, p= 0.101, Fig. 
3.1.1) and in the late intervention group (193.3±15.01 mg vs 235.99±32.85 mg, 
p= 0.294, Fig. 3.1.3 ). On the contrary, in both the early- and late intervention 
groups (as depicted in Fig. 3.1.2 and Fig. 3.1.4 respectively), there was a 
significant difference in the average lymph node weight between the ADM 
and their respective control (saline) groups (949.53±296.30 mg vs 
1410±123.76 mg, p= 0.036 and 559.91±84.14 mg vs 1199.30±250.25 mg, p= 
0.019 in the early- and late intervention group respectively). In the late 
intervention group, the reduction of lymphadenopathy in the ADM-treated 
mice appeared to be slightly more prominent than that of the prednisolone-






Fig. 3.1.1 Bar chart showing the weight of spleens from the saline and ADM-
treated groups. The MRL/lpr mice started treatment at the age of 6 weeks for a 
total period of 18 weeks. Spleens were harvested at the age of 18 weeks and 
the average splenic weight was compared between the two treatment groups 
(n=8 each group). (^p = 0.101) 
 
 
Fig. 3.1.2  Bar chart showing the total weight of lymph nodes harvested from 
cervical and axillary sites of the MRL/lpr mice from the saline and ADM-
treated groups. The MRL/lpr mice started treatment at the age of 6 weeks for a 
total period of 18 weeks (n=8 each group). The total weight of lymph nodes 
were weighed and the average lymph node weight was compared between the 






Fig. 3.1.3 Bar chart showing the weight of spleens from the saline, ADM, and 
prednisolone groups. The MRL/lpr mice started treatment at the age of 12 
weeks for a total period of 6 weeks (n= 7 each group). Spleens were harvested 
at the age of 18 weeks and the average spleen weight was compared among 
the three treatment groups. (^p=0.101, ^^p=0.294, ^^^p= 0.714) 
 
 
Fig. 3.1.4 Bar chart showing the the total weight of the lymph nodes harvested 
from the cervical and axillary sites of the MRL/lpr mice from the saline, ADM, 
and prednisolone groups. The mice started treatment at the age of 12 weeks for 
a total period of 6 weeks (n= 7 each group). Lymph nodes were harvested at 
the age of 18 week. The total weight of the lymph nodes were weighed and the 
average lymph node weight was compared among the three treatment groups 











3.2 Serum levels of anti-dsDNA, anti-Sm, anti-ribosomal P, anti-SSA 52 
and anti-SSA 60 antibodies were not affected by ADM treatment 
 Serum levels of anti-dsDNA, anti-Sm, anti-ribosomal P, anti-SSA 52, 
and anti-SSA 60 antibodies were measured by a multiplexed and 
microparticle-based immunoassay. In both the early- and the late intervention 
groups, the serum levels of the above-mentioned autoantibodies in ADM-
treated mice were not different from their respective control groups (Fig. 3.2.1 









Fig. 3.2.1  Comparison of anti-dsDNA, anti-Sm, anti-RibP, anti-SSA 52 and 
anti-SSA60 autoantibodies levels in the sera of 24 weeks’ old mice treated 
with saline and ADM. The mice started treatment at the age of 6 weeks for a 
total period of 18 weeks (n=6 each group). The peripheral blood was collected 
by cardiac puncture upon sacrifice. Sm, Smith antibody; RibP, Ribosomal P. 











Fig. 3.2.2 Comparison of anti-dsDNA, anti-Sm, anti-RibP, anti-SSA 52 and 
anti-SSA60 autoantibodies levels in the serum of 18 weeks’ old mice treated 
with saline, ADM, and prednisolone. The mice started treatment at the age of 
12 weeksfor a total period of 6 weeks (n=5 each group). The peripheral blood 
was collected by cardiac puncture upon sacrifice.Sm, Smith antibody; RibP, 











p value Saline vs ADM Saline vs Pred ADM vs Pred 
Anti-dsDNA 0.333 0.584 0.868 
Anti-Sm 0.988 0.998 0.989 
Anti-RibP 0.113 0.770 0.039 
Anti-SSA 52 0.755 0.542 0.924 
Anti-SSA 60 0.998 0.232 0.212 
Table 3.2.1 p values of the serum levels of anti-dsDNA, anti-Sm, anti-RibP, 
anti-SSA 52 and anti-SSA 60 in the saline, ADM, and prednisolone groups of 


































 macrophages  
 Splenocytes were isolated and sorted as described in chapter 2.3.5. For 
B220
+
 B cells, the unlabeled fractions that eluted through the MACS magnetic 
separation column were collected and the number of cells was counted by 
hemocytometer. For the remaining three cell populations, the labeled fractions 
from the MACS magnetic separation were sorted by FACSAria cell sorter. 
The number of these cells was calculated based on the exact number of cells 
being sorted by the cell sorter. In the early intervention group (Fig. 3.3.1), the 
number of B220
+
 B cells, CD4
+
 T cells, CD8
+
 T cells, and CD11b
+
 
macrophages in the ADM-treated group tended to be lower than that of the 
saline group. However, the difference was not statistically significant (Table 
3.3.1). In the late intervention group (Fig. 3.3.2 and Table 3.3.2), similar 
trends were also observed for the B220
+
 B cells and CD11b
+
 macrophages as 





cells in the ADM group was comparable with that of the control and 





Fig. 3.3.1 The different populations of splenocytes were isolated at the age of 
24 weeks, using MACS magnetic separation and Aria sorter (n=8 each group). 
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 population. Similary, CD11b
+







 population.  Cell count of B220
+












 cells) Saline (n=8) ADM (n=8) P value 
B220
+
 11.89±4.32 8.33±2.78 0.499 
CD4
+
 1.97±0.49 1.61±0.42 0.585 
CD8
+
 0.85±0.28 0.64±0.18 0.545 
CD11b
+
 1.45±0.75 1.10±0.49 0.700 
Table 3.3.1 Comparison of splenocyte counts in the saline and ADM groups 






Fig. 3.3.2 The different populations of lymphocytes in the spleen were isolated 
using MACS magnetic separation and Aria sorter. The mice started treatment 
at the age of 12 weeks’ old for a total period of 6 weeks (n=7 each group). By 
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 9.91±1.92 9.14±1.22 7.46±1.42 0.909 0.446 0.653 
CD4
+
 2.33±0.28 2.58±0.38 2.04±0.33 0.824 0.782 0.439 
CD8
+
 1.13±0.16 1.15±0.13 0.93±0.12 0.994 0.494 0.422 
CD11b
+
 3.57±1.12 2.69±0.54 3.31±0.70 0.650 0.963 0.802 
Table 3.3.2 Comparison of splenocyte counts in the saline, ADM, and 







3.4 Effect of ADM on proteinuria and hematuria 
 As shown in Fig. 3.4.1 and Fig. 3.4.3, the level of proteinuria tended to 
be lower in the ADM-treated mice of the late intervention group (38.75±8.75 
mg/dL vs 108.57±34.26, p= 0.170) but not in the early intervention group 
(47.5±11.46 mg/dL vs 50±12.08 mg/dL, p= 0.887). Besides, the level of red 
blood cells detected in the urine appeared to be lower in both the early- 
(11.25±9.90 cells/µL vs 20.71±9.60 cells/µL, p=0.519) and late (1.25±1.25 
cells/µL vs 14.29±11.1 cells/µL, p= 0.802) intervention groups (Fig. 3.4.2 and 
Fig. 3.4.4 respectively).  
 
 
Fig. 3.4.1  Comparison of the levels of proteinuria in the of the 24 weeks old 







Fig. 3.4.2 Comparison the levels of red blood cells detected in the urine of the 
24 week old mice of the ADM and saline groups (n=8 each group). (*p= 0.519) 
 
 
Fig. 3.4.3 Bar chart showing the levels of proteinuria detected in the 18 weeks 
old mice of the saline, ADM, and prednisolone groups. The mice started 
treatment at the age of 12 weeks for a total period of 6 weeks (n=7 each group). 









Fig. 3.4.4 Bar chart showing the levels of red blood cells detected in the urine 
of 18 weeks’ old mice of the saline, ADM, and prednisolone groups. The mice 
started treatment at the age of 12 weeksfor a total period of 6 weeks (n=7 each 




















3.5 Renal deposition of C1q, C3, anti-dsDNA antibody, IgA, IgG, and IgM 
immunoglobulins were affected by ADM treatment in the late 
intervention group 
 Immunofluorescent staining of the kidney cryosections for C1q, C3, 
anti-dsDNA antibody, IgA, IgG and IgM were performed in mice of different 
treatment groups. The staining was assessed in a blinded manner. In the early 
intervention group, there was no significant difference in all the markers 
between the ADM group and the controls (Fig 3.5.1- 3.5.6). However, in the 
late intervention group, ADM treatment apparently reduced the glomerular 
depositions of C1q complement, anti-dsDNA antibody, IgA, IgG and IgM as 
compared to the saline group (Fig. 3.5.8- 3.5.13). However, the mean 
fluorescence intensity showed no significant difference between the treated 
groups and the control group in both the early- (Fig. 3.5.7 and Table 3.5.1) and 











Fig. 3.5.1  Representative immunofluorescent images of C1q deposition in 
the kidney cryosections. The MRL/lpr mice started treatment at the age of 
6 weeks for a total period of 18 weeks (n=8 each group).  Sagittal 
cryosections (6 µm) of kidneys were obtained from saline (A and C) and 

















Fig. 3.5.2 Representative immunofluorescent images of C3 deposition in 
the kidney cryosections. The MRL/lpr mice started treatment at the age of 
6 weeks for a total period of 18 weeks (n=8 each group). Sagittal 
cryosections (6 µm) of kidneys were obtained from saline (A and C) and 


















Fig. 3.5.3  Representative immunofluorescent images of the deposition of 
anti-dsDNA autoantibody in the kidney cryosections. The MRL/lpr mice 
started treatment at the age of 6 weeks for a total period of 18 weeks (n=8 
each group).  Sagittal cryosections (6 µm) of kidneys were obtained from 
saline (A and C) and ADM groups (B and D). The arrows indicate the 
























Fig. 3.5.4 Representative immunofluorescent images of IgA deposition in 
the kidney cryosections. The MRL/lpr mice started treatment at the age of 
6 weeks for a total period of 18 weeks (n=8 each group).  Sagittal 
cryosections (6 µm) of kidneys were obtained from saline (A and C) and 
























Fig. 3.5.5 Representative immunofluorescent images of IgG deposition in 
the kidney cryosections. The MRL/lpr mice started treatment at the age of 
6 weeks for a total period of 18 weeks (n=8 each group).  Sagittal 
cryosections (6 µm) of kidneys were obtained from saline (A and C) and 



















Fig. 3.5.6 Representative immunofluorescent images of IgM deposition in 
the kidney cryosections. The MRL/lpr mice started receiving treatment at 
the age of 6 week old for a total period of 18 weeks (n=8 each group).  
Sagittal cryosections (6 µm) of kidneys were obtained from saline (A and 























Fig. 3.5.7 Bar chart showing the MFI of the different markers deposited on 
the kidney glomeruli after normalizing with mean background intensity. 
The MRL/lpr mice started receiving treatment at the age of 6 week old for 
a total period of 18 weeks (n=3 each group).   
 
Table 3.5.1 Comparison of the FI of the glomerular deposition of different 







 Mean rank  
MFI  Saline (n=3) ADM (n=3) P value 
C1q 3.00 4.00 0.513 
C3 4.00 3.00 0.513 
Anti-dsDNA 3.67 3.33 0.827 
IgA 3.00 4.00 0.513 
IgG 4.00 3.00 0.513 








































Fig. 3.5.8 Representative immunofluorescent images of the deposition of C1q 
in the kidney cryosections. The mice started treatment at the age of 12 weeks 
for a total period of 6 weeks (n=7 each group). Sagittal cryosections (6 µm) of 
kidneys were obtained from saline (A and B), ADM, (C and D) and 






































Fig. 3.5.9 Representative immunofluorescent images of the deposition of C3 
in the kidney cryosections. The mice started treatment at the age of 12 weeks’ 
old for a total period of 6 weeks (n=7 each group). Sagittal cryosections (6 µm) 
of kidneys were obtained from saline (A and B), ADM, (C and D) and 






































Fig. 3.5.10 Representative immunofluorescent images of the deposition of 
anti-dsDNA in the kidney cryosections. The mice started treatment at the age 
of 12 weeks’ old for a total period of 6 weeks (n=7 each group). Sagittal 
cryosections (6 µm) of kidneys were obtained from saline (A and B), ADM, 
(C and D) and prednisolone groups (E and F). The arrows indicate the 

























































Fig. 3.5.11 Representative immunofluorescent images of the deposition of IgA 
in the kidney cryosections. The mice started treatment at the age of 12 weeks’ 
old for a total period of 6 weeks (n=7 each group). Sagittal cryosections (6 µm) 
of kidneys were obtained from saline (A and B), ADM, (C and D) and 
























































Fig. 3.5.12 Representative immunofluorescent images of the deposition of IgG 
in the kidney cryosections. The mice started treatment at the age of 12 weeks’ 
old for a total period of 6 weeks (n=7 each group). Sagittal cryosections (6 µm) 
of kidneys were obtained from saline (A and B), ADM, (C and D) and 

























































Fig. 3.5.13 Representative immunofluorescent images of the deposition of 
IgM in the kidney cryosections. The mice started treatment at the age of 12 
week old for a total period of 6 weeks (n=7 each group). Sagittal cryosections 
(6 µm) of kidneys were obtained from saline (A and B), ADM, (C and D) and 

















Fig. 3.5.14 Bar chart showing the MFI of the different markers deposited 
on the kidney glomeruli after normalizing with mean background intensity. 
The MRL/lpr mice started receiving treatment at the age of 12 week old 
for a total period of 6 weeks (n=3 each group).   
 
Table 3.5.2 Comparison of the MFI of the glomerular deposition of different 






 Mean rank  
MFI Saline (n=3) ADM (n=3) Prednisolone 
(n=3) 
P value 
C1q 7.00 5.33 2.67 0.148 
C3 6.33 5.33 3.33 0.393 
Anti-dsDNA 7.33 3.33 4.33 0.177 
IgA 6.00 4.67 4.33 0.733 
IgG 6.67 2.00 6.33 0.066 















B cell proliferation in cultured splenocytes from MRL/Fas
lpr 
mice at low 
dose of CpGb 
 Due to the apparent reduction of the depositions of complements and 
antibodies in the kidney tissues of the late intervention group, we sought to 
examine the effect of ADM in the proliferation and apoptosis of lymphocytes 
in vitro. Splenocytes were extracted from untreated MRL/lpr mice as 
described earlier. These cells were first labelled with CFSE, which is 
commonly used in quantifying cell proliferation and monitoring cell migration 
in vitro and in vivo (Parish et al. 2009). CFSE is highly permeable to the cell 
membranes due to its two acetate side chains (Parish et al. 2009). Once it 
permeates into the cells, the acetate groups are cleaved by intracellular 
esterases, leading to the emission of fluorescence (Parish et al. 2009). The 
remaining succinimidyl moiety forms amide bond with intracellular amine 
groups in the labelled cells and can be inherited to their daughter cells after 
either cell division or cell fusion (Parish et al. 2009). It has been reported that 
CFSE-labelled lymphocytes could be detected up to eight weeks after injection 
into mice (Weston and Parish 1990).  
In the current study, the labelled cells were stimulated with a potent B 
cell stimulant CpGb and T cell stimulant anti-CD3/CD28 respectively, with 









 T cells labelled with CFSE respectively, 
after 72hr of incubation. At low concentration of CpGb (<0.1 µM), the 




B cells appeared to be lower in 
the ADM group. However, as the concentration of CpGb increased, the 
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B cells increased in both the 
ADM and control groups. This increase reached the maximum point at the 
concentration of 0.1 µM. On the other hand, there was no difference in the 




 T cells, regardless of the 
concentration of anti-CD3/CD28 antibodies.  
 Besides proliferation, the effect of ADM on apoptosis was also 
examined by using APC-conjugated Annexin V staining. During the early 
stage of apoptosis, the membrane phospholipid asymmetry is disrupted and 
results in the exposure of phosphatidylserine (PS) at the surface of the cells 
(Koopman et al. 1994). Being one of the members in the family of calcium-
dependent phospholipid-binding proteins, Annexin V recognizes and binds to 
PS (Koopman et al. 1994).  In other words, Annexin V acts as an early apoptosis 
marker and it can be distinguished from necrotic cells by using a late cell 
death marker such as 7-AAD (Koopman et al. 1994). Fig. 3.6.2 and 3.6.4 








 T cells 
stained by Annexin V respectively, after 72hr of incubation. The percentages 




B cells appeared to be higher in the 
ADM group at low concentration of CpGb (<0.1 µM). When the concentration 





cells also decreased in both ADM and control groups. Again, there was no 




 T cells, 




Fig. 3.6.1 Splenocytes from untreated MRL/lpr mice (12-15 weeks’ old) were 
incubated with CpGb in the presence of ADM for 72 hours (n=2). For the 
control experiment, the splenocytes were stimulated with CpGb for 72 hours, 
without the addition of ADM. The percentages of B220
+
 cells incorporated 
with CFSE were shown.  
 
 
Fig. 3.6.2 Splenocytes from untreated MRL/lpr mice (12-15 weeks’ old) were 
incubated with CpGb in the presence of ADM for 72 hours (n=2). For the 
control experiment, the splenocytes were stimulated with CpGb for 72 hours, 
without the addition of ADM. The percentages of B220
+
 cells positively 




Fig. 3.6.3 Splenocytes from untreated MRL/lpr mice (12-15 weeks’ old) were 
incubated with anti-CD3/CD28 antibodies in the presence of ADM for 72 
hours (n=2). For the control experiment, the splenocytes were stimulated with 
anti-CD3/CD28 antibodies for 72 hours, without the addition of ADM. The 
percentages of CD4
+
 T cells incorporated with CFSE were shown.   
 
 
Fig. 3.6.4 Splenocytes from untreated MRL/lpr mice (12-15 weeks’ old) were 
incubated with anti-CD3/CD28 antibodies in the presence of ADM for 72 
hours (n=2). For the control experiment, the splenocytes were stimulated with 
anti-CD3/CD28 antibodies for 72 hours, without the addition of ADM. The 
percentages of CD4
+
 T cells positively labelled with APC-conjugated Annexin 




CHAPTER 4 DISCUSSION 
 Over the past two decades, the effect of ADM has been addressed in 
several pathological conditions such as stroke, renal impairment and metabolic 
syndrome. However, to date, the information on the impact of ADM on the 
disease progression and development of GN in SLE murine model is scarce. 
Hence, this study provides an insight into the possible roles of novel biological 
markers and new therapeutic opportunity of ADM in the pathogenesis of SLE.  
In patients with SLE, proteinuria is one of the biomarkers of the 
activity of nephritis (Reyes-Thomas et al. 2011). The development of 
proteinuria is closely associated with MCs, which form part of the functional 
unit in the glomerular barrier (Schlöndorff and Banas 2009). Glomerular MCs 
work closely with endothelial cells and podocytes in maintaining the structure 
and function of the glomerular barrier (Schlöndorff and Banas 2009; 
Haraldsson et al. 2008). MCs possess contractible property and are able to 
secrete several inflammatory mediators, including IL-1, PDGF and NO 
(Schlöndorff and Banas 2009). Due to its ability to contract and relax the 
capillaries, MCs are proposed to affect the glomerular filtration rate by 
modulating the rate of plasma flow and filtration surface area (Parameswaran 
et al. 2001). Hence, the increase in MCs proliferation and injury could result in 
proteinuria (Schlöndorff and Banas 2009). In the current study, it was found 
that ADM was able to reduce proteinuria and hematuria albeit the difference in 
the reduction was not statistically significant. This finding is in keeping with a 
few of the previous studies. In an early study that examined the effect of ADM 
on cultured endothelial cells and MCs, it was reported that ADM strongly 
suppressed PDGF-stimulated thymidine incorporation into those cells 
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(Michibata et al. 1998). A reduction in [
3
H]thymidine incorporation and 
augmentation in apoptotic markers such as cytoplasmic DNA fragmentation 
and caspases activation were observed when cultured glomerular MCs were 
treated with ADM (Parameswaran et al. 1999). In addition, a recent study 
demonstrated that exogenous ADM infusion significantly increased apoptosis 
in MCs and reduced glomerular monocyte infiltration during acute anti-Thy-
1.1 antibody-induced GN rat model (Plank et al. 2005).  The inhibitory effect 
of ADM exhibited in the aforementioned studies was shown to be mediated 
via the cAMP-MAPK signalling pathway (Filippatos et al. 2001; 
Parameswaran et al. 1999).  Besides exerting its inhibitory effect on MCs, 
ADM was found to relax the cells by increasing the intracellular cAMP level, 
leading to an increase in the glomerular filtration rate which may attenuate the 
progression of lupus nephritis (Parameswaran et al. 2001). While the present 
study was not designated to investigate the exact mechanism on how ADM 
inhibits the proliferation and/or induces apoptosis in MCs, the findings of the 
current experiments reported in this thesis and those of the previous reports 
support a close relationship in between ADM and MCs in the development of 
lupus nephritis.  
In patients with SLE, the prevalence of lymphadenopathy is 
approximately 25-50% and it was reported to be positively correlated with 
disease activity of SLE (Kitsanou et al. 2000). The most common nodal 
groups involved were the cervical, mesenteric, axillary, and inguinal nodes 
(Eisner et al. 1996). As shown by lymph node biopsies, the pathology of 
lymphadenopathy was characterized by necrosis and infiltration of histiocytes, 
lymphocytes, plasma cells, and immunoblasts (Eisner et al. 1996). Similar 
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manifestation can be observed in the MRL/lpr mice as one of their 
pathological features is the presence of splenomegaly and lymphadenopathy 
due to the defective Fas gene (Bettinardi and Brugnoni 1997). In these mice, 
the enlargement of lymph nodes and splenomegaly are mainly attributed by 






 DN T cells comprise of more than 90% of the infiltrating cells 
(Singer et al. 1986; Mountz et al. 1990; Cohen and Eisenberg 1992). The 
regulation of T and B cells is known to play a critical role in the pathogenesis 
of SLE (Choi et al. 2012). The upregulation of DN T cells in lupus mice 
contributes to the disease progression by secreting pro-inflammatory cytokines 
and activate antibodies formation by plasma cells (Shimp et al. 2012). In 
addition, aberrant B cells which also behave as APCs present autoantigens and 
induce Th2 cells activation, leading to augmentation of autoantibody 
production (Shimp et al. 2012). Hence, the suppression of the autoreactive T 
and B cells could alleviate the disease. In the current study, ADM was found 
to significantly reduce lymphadenopathy but not splenomegaly. Nonetheless, 
the overall splenomegaly was slightly reduced in the ADM group as compared 
with the saline group. In addition, flow cytometry results showed that the 
overall splenocytes counts: B220
+
 B cells, CD4
+
 T cells, CD8
+ 
T cells and 
CD11b
+ 
macrophages were reduced by the treatment of ADM. Of all these 
cells, the effect of ADM on the reduction of the B220
+
 B cells appeared to be 
more prominent as compared with that of the other three cell populations. 
From this, it was deduced that ADM might possess anti-proliferative effect 
and it could be exerted on the aberrant lymphocytes, particularly the B cells in 
this case. In support of the deduction, an in vitro assay using splenocytes 
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extracted from the MRL/lpr mice was performed. These splenocytes were 
stimulated with CpGb oligodeoxynucleotide (B cell stimulant) and anti-
CD3/CD28 antibodies (T cell stimulant) at different concentrations, coupled 
with the treatment of ADM. It was found that at a lower concentration of 
CpGb, the proliferation of B220
+
 B cells was reduced while the apoptosis of 
these cells was increased by the treatment of ADM. Hence, ADM may act as 
an anti-proliferative/pro-apoptotic regulator in the context of B lymphocyte 
proliferation. In fact, the role of ADM in apoptosis has been described in 
several studies. In a study using cultured rat VSMCs, ADM showed dose-
dependent inhibition of the FCS-stimulated proliferation of VSMCs (Kano et 
al. 1996). As discussed earlier, ADM was also found to strongly suppress MCs 
proliferation and reduce glomerular monocyte infiltration in both in vitro and  
in vivo studies, via the cAMP-MAPK signalling pathway (Parameswaran et al. 
1999; Plank et al. 2005; Filippatos et al. 2001).  Based on these reports, the 
reduction in the lymphadenopathy and splenomegaly in this study could be 
proposed to be attributed to the anti-proliferative/pro-apoptotic effect of ADM. 
However, more work needs to be done to determine the exact mechanism of 
ADM on the proliferation/apoptosis of these lymphocytes.  
 Active lupus is usually characterized by abnormal elevation of 
autoantibodies in the system (Gladman et al. 1999). This phenomenon can be 
explained by the dsyregulation in the clearance of apoptotic bodies due to the 
impairment in the phagocytic function of macrophages and monocytes in SLE 
patients (Ren et al. 2003; Herrmann et al. 1998). As a result, apoptotic bodies 
especially nucleosomes were phagocytosed and presented by the APCs which 
subsequently stimulate the production of antibodies directed to self- and 
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nuclear antigens (Gaipl et al. 2007). In this study, the serum level of a number 
of autoantibodies (anti-dsDNA, anti-Sm, anti-ribosomal P, anti-SSA 52 and 
anti-SSA 60) was found to be unaffected by the treatment of ADM in both the 
early- and late intervention groups.  In contrast, the immunofluorescent 
staining results displayed striking reduction of the depositions of anti-dsDNA, 
IgA and IgM antibodies and complement in the glomeruli in the ADM-treated 
mice of the late intervention group.  However, in the early- intervention group, 
ADM group showed no drastic difference from the saline group in the 
glomerular deposition of autoantibodies, anti-dsDNA and complement. As the 
mice in the early intervention group started receiving treatment before the 
onset of the lupus-like disease, these findings indicated that ADM most likely 
exerts its protective role against glomerulonephritis after the onset of the 
disease. In addition, the effect of ADM is probably regulated locally in the 
kidney without affecting the peripheral autoantibody levels. In lupus nephritis, 
infiltrating monocytes and resident macrophages contribute to the local 
cytokines (e.g. IL-1, IL-6, IFN-γ and TNF‐α) and NO (Gonzalez-Rey 2006).  
These pro-inflammatory modulators play a critical role in activating B and Th 
cells which the latter subsequently induce the antibodies production of plasma 
cells (Souza-Moreira et al. 2011). It was demonstrated in a mouse septic shock 
model that ADM inhibited TNF-α and IL-6 production by activated 
macrophages, thus preventing endotoxin-induced lethality (Gonzalez-Rey et al. 
2006). Moreover, ADM was also reported to ameliorate inflammation-induced 
colitis by suppressing TNF-α production by activated macrophages (Gonzalez-
Rey 2006). Based on these, it is proposed that the reduction of autoantibody 
and complement deposition in the kidney in the current study might be 
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mediated by the modulation of pro-inflammatory cytokines. In addition, the 
reduction of autoantibody deposition in the glomeruli appeared to be 
comparable between the ADM and the prednisolone groups. Being one of the 
most commonly prescribed corticosteroids, prednisolone is usually combined 
with cyclophosphamide or mycophenolate mofetil to treat severe lupus 
nephritis (Borchers et al. 2012). While this treatment regime is able to delay 
the progression to renal failure, it also gives rise to severe adverse effects such 
as major infection, steroid-induced diabetes mellitus and hypertension 
(Borchers et al. 2012; Bootsma et al. 1995).  Conversely, ADM is essentially 
not associated with severe side effects as it is endogenously secreted in the 
physiological system (Souza-Moreira et al. 2011). Furthermore, the relatively 
small size and hydrophilic characteristic of ADM enable it to gain access to 
the site of inflammation easily (Souza-Moreira et al. 2011). Hence, the 
protective role of ADM might enable it to become a potential candidate as an 
adjunctive therapy of lupus nephritis.  
There are a few limitations in this study. First, the sample size and the 
duration of treatment regime might be insufficient to generate statistical 
significance in the splenic weight, proteinuria, hematuria, and in vitro assay. 
In the immunofluorescent staining, although the images displayed apparent 
reduction in the staining in the late intervention group, the MFI showed no 
statistical significance in the treatment groups as compared with the control 
group. This is because the number of kidney sections examined was only three 
per treatment group and it should be improved by examining the kidney 
sections of all the mice. While it is reported in most of the studies that the 
disease manifestation in the MRL/lpr mice starts at around 12 weeks of age, 
74 
 
the IHC results revealed that the disease progression is not at the full-blown 
state (data not shown) (Gulinello and Putterman 2011; Koopman and Gay 
1988). This discrepancy was also reported in a recent study that examined the 
effect of a derivative of Geldanamycin on the development of SLE using the 
MRL/lpr mice (Shimp et al. 2012). It was reported that the proteinuria and 
glomerulonephritis were not noticeably increased in MRL/lpr mice even at the 
age of 18 weeks old (Shimp et al. 2012). As a result, it will be more 
challenging to determine the significant difference between the treated and 
untreated groups. Therefore, the confirmation of disease development should 
best be examined by serological analysis and proteinuria before starting the 
treatment. In addition, ADM and prednisolone were administered to the mice 
at a fixed concentration regardless of the increment of the body weight of the 
mice during the treatment period. Hence, this limitation should be improved 










CHAPTER 5 CONCLUSION 
 In summary, ADM treatment significantly reduced lymphadenopathy 
but not splenomegaly in both the early- and late intervention groups. On the 
other hand, the level of a number of autoantibodies in the serum was not 
affected by exogenous ADM administration. MRL/lpr mice treated with ADM 
tended to have less proteinuria and hematuria. The cell count of the splenocyte 
population: B220
+
 B cells, CD4
+
 T cells, CD8
+
 cells and CD11b
+
 
macrophages showed insignificant reduction by the treatment of ADM.  In the 
late intervention group, glomerular C3, C1q, anti-dsDNA, IgA, IgG and IgM 
depositions were not significantly reduced by exogenous ADM. In vitro, ADM 
treatment decreased the proliferation but increased the apoptosis of B220
+
 B 
cells but not CD4
+
 T cells at low concentration of CpGb. Taken together these 
findings, it was suggested that ADM might play a role in regulating the 
proliferation/apoptosis of B220
+














CHAPTER 6 FUTURE WORK 
 The findings of the study reported in this thesis suggested that ADM 
may possess local inhibitory effect on the production of cytokine in the 
glomeruli and proliferation of B220
+
 cells in a lupus murine MRL/lpr model. 
However, its mechanism of action remains unclear because there is so far no 
study reporting the effect of ADM in this mouse model. As reported in other 
similar studies, ADM has been demonstrated to exert its inhibitory effect on 
cell proliferation by elevating intracellular cAMP which stimulates PKA that 
leads to the MAPK signalling pathway (Parameswaran et al. 2001; Plank et al. 
2005; Chini et al. 1997). The outcome of this pathway is associated with 
increased apoptosis, decreased proliferation, migration and ROS production in 
rat MCs and VSMCs (Parameswaran et al. 2001). Since the biological effect 
of ADM is mediated by CGRP1 and ADM receptors which involve the 
upregulation of cAMP as the secondary messenger, it is postulated that ADM 
may apply the same mechanism in the MRL/lpr mice (Kuwasako et al. 2011). 
Thus, in future study, the mechanism of ADM can be evaluated by using 
cultured MCs and splenic B cells extracted from MRL/lpr mice. These cells 
can then be treated with and without ADM for different time points. The 
expression of ADM, cAMP, PKA and MAPK as well as pro-inflammatory 
cytokines such as IL-6, TNF-α and IL1-β in the cultured cells and cultured 
supernatant should be determined by Western blot analysis and ELISA 
respectively. In addition, splenic lymphocytes can be sorted by flow cytometry 
to purify B220
+
 B cells and CD4
+
 T cells. These cells can then be stimulated 
with or without ADM in a range of concentrations and the mRNA level of 
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CGRP1/ ADM receptors and apoptosis/ survival factors (e.g. caspases, Bcl-2) 
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